ReviewHuntington's disease: The current state of research with peripheral tissues
Introduction
Huntington's disease (HD) is a devastating neurodegenerative disorder caused by an expansion of the CAG repeat in the IT-15 gene which codes for a protein named huntingtin (htt) (HDCRG, 1993). Htt, a very large protein that is highly conserved in vertebrates during evolution (Gissi et al., 2006), is ubiquitously expressed in human tissues, suggesting pivotal (yet still unidentified) roles in and outside the central nervous system (CNS). The pathological expansion of the polyglutamine (polyQ) tract results in mutant htt becoming cytotoxic in patients' brain tissues (especially in the basal ganglia and cortex), causing early dysfunction and progressive atrophy of these regions that results in chorea and other movement disorders associated with cognitive and behavioral symptoms. Although the neurological symptoms predominate, they are not the sole manifestation of HD. Early reports, before the discovery of the HD gene, described pathological phenotypes in peripheral tissues of HD patients, including weight loss (Sanberg et al., 1981, Djoussé et al., 2002, Hamilton et al., 2004, Aziz et al., 2009) and altered glucose homeostasis (Podolsky and Leopold, 1977; Podolsky et al.,1972). Other reported changes included sub-cellular abnormalities in fibroblasts (Menkes and Stein, 1973, Leonardi et al., 1978, Beverstock, 1984), lymphocytes (Pettegrew et al., 1981, McGovern and Webb, 1982) and erythrocytes (Pettegrew et al., 1980, Zanella et al., 1980) from HD patients. Growing evidence now suggests that cells from peripheral tissues of HD patients bear abnormalities related to the expression of mutant htt. These patients' peripheral cells therefore provide invaluable models for studying the molecular mechanisms through which endogenous htt leads to neuronal cell dysfunction.
This review focuses on current knowledge of peripheral tissue alterations in HD patients and in HD animal models. It also highlights how this information might be used to identify biomarkers for the progression of the disease as well as new therapeutic options.
Section snippets
Evidence for cardiac dysfunction in HD patients
From the clinical point of view, multiple epidemiological studies have shown that heart disease is the second leading cause of death in patients with HD (Chiu and Alexander, 1982, Lanska et al., 1988aLanska et al., 1988b, Sørensen and Fenger, 1992; Table 1A). These findings notwithstanding, heart disease has not been found to be more frequent in HD patients than in controls (Lanska et al., 1988a).
Another potentially important feature of heart disease in HD concerns altered autonomic system
Mutant htt and intracellular aggregate formation in peripheral tissues
A prominent feature of mutant htt is its tendency to form insoluble protein aggregates in vivo (Davies et al., 1997). Indeed, formation of htt protein aggregates in affected individuals' brains is the neuropathologic hallmark of HD (DiFiglia et al., 1997). PolyQ aggregates in HD show many of the attributes of amyloid fibrils, (Sugaya et al., 2007) given that htt aggregates form in several structural/molecular states, including nucleation of misfolded htt, (Sugaya et al., 2007) formation of
Conclusion
Current evidence, derived from intensive research efforts by many investigators over a long time-span, increasingly favors a widespread toxic effect of mutated htt in the peripheral tissues of patients with HD. But how can these observations help in the development of effective medications to slow or arrest the neurodegenerative process in HD? A drug discovery project needs to identify targets, defined as cellular components whose modulation is anticipated to have a therapeutic benefit for
Acknowledgments
The authors wish to thank patients and their families (Associazione Mauro Emolo O.N.L.U.S.) for their precious support. We also gratefully acknowledge Dr. Simonetta Sipione and two anonymous reviewers for their helpful comments on the manuscript.
References (157)
- et al.
Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression
Neurobiol. Dis.
(2002) - et al.
Cellular immune responses in Huntington's disease (H.D.). Detection of H.D. and multiple sclerosis (M.S.) brain antigenicity by H.D. but not M.S. lymphocytes
Cell. Immunol.
(1977) Huntingtin aggregation and toxicity in Huntington's disease
Lancet
(2003)- et al.
Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease
Neuroscience
(2007) - et al.
Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease.
Brain Res. Rev.
(2008) Transcriptional dysregulation in Huntington's disease
Trends Neurosci.
(2000)Transcriptional signatures in Huntington's disease
Prog. Neurobiol.
(2007)- et al.
Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients
Biochem. Biophys. Res. Commun.
(2007) - et al.
Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347
Mol. Cell. Neurosci.
(2008) - et al.
Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration
Cell
(2006)
Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
Cell
Energy balance in early-stage Huntington disease
Am. J. Clin. Nutr.
The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease
Neuroscience
The metabolic profile of early Huntington's disease: a combined human and transgenic mouse study
Exp. Neurol.
The limbic–hypothalamic–pituitary–adrenal axis in Huntington's disease
Biol. Psychiatry
Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea
J. Neurol. Sci.
The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea
Neurosci. Lett.
Autophagy and neurodegeneration: when the cleaning crew goes on strike
Lancet Neurol.
PGC-1alpha, a new therapeutic target in Huntington's disease?
Cell
Cardiac dysfunction in the R6/2 mouse model of Huntington's disease
Neurobiol. Dis.
Molecular dynamics simulation study on the structural stabilities of polyglutamine peptides
Comput. Biol. Chem.
Disease-specific induced pluripotent stem cells
Cell
Anterograde transport of brain-derived neurotrophic factor and its role in the brain
Nature
Chromosomal profiles of gene expression in Huntington's disease
Brain
Autonomic nervous system function in Huntington's disease
J. Neurol. Neurosurg. Psychiatry
Complex I defect in muscle from patients with Huntington's disease
Ann. Neurol.
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Nature
Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications
Rev. Neurosci.
Weight loss in Huntington disease increases with higher CAG repeat number
Neurology
Increased hypothalamic–pituitary–adrenal axis activity in Huntington's disease
J. Clin. Endocrinol. Metab.
Islet beta-cell area and hormone expression are unaltered in Huntington's disease.
Histochem. Cell Biol.
Cardiovagal modulation upon postural change is altered in Huntington's disease
Eur. J. Neurol.
Immunological studies in Huntington's disease
Ann. Neurol.
Impairment of the ubiquitin–proteasome system by protein aggregation
Science
The current state of research with peripheral tissues in Huntington disease
Hum. Genet.
The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis
Hum. Mol. Genet.
Progressive alterations in the hypothalamic–pituitary–adrenal axis in the R6/2 transgenic mouse model of Huntington's disease
Hum. Mol. Genet.
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease
J. Exp. Med.
Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease
Proc. Natl. Acad. Sci. U. S. A.
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
Nature
Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington's disease
J. Neurol.
Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation
J. Neurosci.
Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene
Proc. Natl. Acad. Sci. U. S. A.
Causes of death in Huntington's disease
Med. J. Aust.
Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects
Cell Death Differ.
Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients
Am. J. Med. Genet. B. Neuropsychiatr. Genet.
Akt is altered in an animal model of Huntington's disease and in patients
Eur. J. Neurosci.
Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates
J. Proteome Res.
Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
Science
Weight loss in early stage of Huntington's disease
Neurology
Cited by (148)
Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease
2024, Neurobiology of DiseasePan-neuronal expression of human mutant huntingtin protein in Drosophila impairs immune response of hemocytes
2022, Journal of NeuroimmunologyThe microbiota-gut-brain axis in Huntington's disease
2022, International Review of NeurobiologySystemic manifestation and contribution of peripheral tissues to Huntington's disease pathogenesis
2021, Ageing Research ReviewsCitation Excerpt :These results suggest that mutant HTT gradually causes retinal dysfunction and degeneration (Table 10). Blood cells are among the most accessible cells in the organism, so the wide range of effects of pathogenic huntingtin on different blood cells such as erythrocytes and leukocytes has been extensively investigated (for a review of this work, see (Sassone et al., 2009)). Recently, microarray and RNA-seq analyses done from HD blood and brain samples have indicated that the gene expression changes induced in the brain by HTT-polyQ are similar to those found in blood cells, which suggests that the blood can be used to investigate HD in a non-invasive manner in humans (Mina et al., 2016; Moss et al., 2017) and monkeys (Clever et al., 2019).